Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/23601
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gerretsen, Philip | |
dc.contributor.author | Muller, Daniel J. | |
dc.contributor.author | Tiwari, Arun | |
dc.contributor.author | Mamo, David | |
dc.contributor.author | Pollock, Bruce G. | |
dc.date.accessioned | 2017-11-09T08:42:50Z | |
dc.date.available | 2017-11-09T08:42:50Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Gerretsen, P., Müller, D. J., Tiwari, A., Mamo, D., & Pollock, B. G. (2009). The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues in clinical neuroscience, 11(4), 363-376. | en_GB |
dc.identifier.issn | 12948322 | |
dc.identifier.uri | https://www.um.edu.mt/library/oar//handle/123456789/23601 | |
dc.description.abstract | We currently rely on large randomized controlled trials and meta-analyses to make clinical decisions; this places us at a risk of discarding subgroup or individually specific treatment options owing to their failure to prove efficacious across entire populations. There is a new era emerging in personalized medicine that will focus on individual differences that are not evident phenomenologically. Much research is directed towards identifying genes, endophenotypes, and biomarkers of disease that will facilitate diagnosis and predict treatment outcome. We are at the threshold of being able to predict treatment response, primarily through genetics and neuroimaging. In this review we discuss the most promising markers of treatment response and adverse effects emerging from the areas of pharmacogenetics and neuroimaging in depression and schizophrenia. | en_GB |
dc.language.iso | en | en_GB |
dc.publisher | Les Laboratoires Servier | en_GB |
dc.rights | info:eu-repo/semantics/openAccess | en_GB |
dc.subject | Personalized medicine | en_GB |
dc.subject | Pharmacogenetics -- Social aspects | en_GB |
dc.subject | Neuroimmunology | en_GB |
dc.subject | Antipsychotic drugs | en_GB |
dc.subject | Antidepressants | en_GB |
dc.subject | Schizophrenia -- Diagnosis | en_GB |
dc.title | The intersection of pharmacology, imaging, and genetics in the development of personalized medicine | en_GB |
dc.type | article | en_GB |
dc.rights.holder | The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder | en_GB |
dc.description.reviewed | peer-reviewed | en_GB |
dc.publication.title | Dialogues in Clinical Neuroscience | en_GB |
Appears in Collections: | Scholarly Works - FacM&SPsy |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
DialoguesClinNeurosci-11-363.pdf | 2.86 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.